The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Hot Stocks   »  Analyzing the Price-to-Earnings Ratio of Clover He...

Analyzing the Price-to-Earnings Ratio of Clover Health Investments Corp. (CLOV)

The 36-month beta value for CLOV is also noteworthy at 2.03. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 rating it as “hold,” and 1 rating it as “sell.”

The average price estimated by analysts for CLOV is $1.65, which is $0.55 above than the current price. The public float for CLOV is 366.89M, and at present, short sellers hold a 6.19% of that float. The average trading volume of CLOV on September 19, 2023 was 8.29M shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


CLOV) stock’s latest price update

The stock of Clover Health Investments Corp. (NASDAQ: CLOV) has decreased by -2.65 when compared to last closing price of 1.13.Despite this, the company has seen a loss of -18.52% in its stock price over the last five trading days. Zacks Investment Research reported 2023-08-30 that Here is how Clover Health Investments, Corp. (CLOV) and Axcella Health Inc. (AXLA) have performed compared to their sector so far this year.

CLOV’s Market Performance

Clover Health Investments Corp. (CLOV) has experienced a -18.52% fall in stock performance for the past week, with a -19.71% drop in the past month, and a 21.92% rise in the past quarter. The volatility ratio for the week is 7.24%, and the volatility levels for the past 30 days are at 7.29% for CLOV. The simple moving average for the past 20 days is -14.75% for CLOV’s stock, with a 3.83% simple moving average for the past 200 days.

Analysts’ Opinion of CLOV

Many brokerage firms have already submitted their reports for CLOV stocks, with Cowen repeating the rating for CLOV by listing it as a “Market Perform.” The predicted price for CLOV in the upcoming period, according to Cowen is $3 based on the research report published on February 02, 2022 of the previous year 2022.

CLOV Trading at -10.63% from the 50-Day Moving Average

After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.17% of loss for the given period.

Volatility was left at 7.29%, however, over the last 30 days, the volatility rate increased by 7.24%, as shares sank -18.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.47% upper at present.

During the last 5 trading sessions, CLOV fell by -18.52%, which changed the moving average for the period of 200-days by -10.57% in comparison to the 20-day moving average, which settled at $1.2778. In addition, Clover Health Investments Corp. saw 18.34% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CLOV starting from Loengard Anna U, who purchase 11,000 shares at the price of $1.30 back on Sep 06. After this action, Loengard Anna U now owns 10,000 shares of Clover Health Investments Corp., valued at $14,300 using the latest closing price.

Stock Fundamentals for CLOV

Current profitability levels for the company are sitting at:

  • -10.35 for the present operating margin

The net margin for Clover Health Investments Corp. stands at -9.72. The total capital return value is set at -80.57, while invested capital returns managed to touch -74.31. Equity return is now at value -74.40, with -20.50 for asset returns.

Based on Clover Health Investments Corp. (CLOV), the company’s capital structure generated 1.69 points at debt to equity in total, while total debt to capital is 1.66. Total debt to assets is 0.72, with long-term debt to equity ratio resting at 1.16. Finally, the long-term debt to capital ratio is 1.14.

When we switch over and look at the enterprise to sales, we see a ratio of 0.16, with the company’s debt to enterprise value settled at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.42.


In summary, Clover Health Investments Corp. (CLOV) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.